Actuate Therapeutics, Inc. Company Profile, Contacts & Intelligence

Actuate Therapeutics, Inc. Overview

Actuate Therapeutics, Inc. (NASDAQ: ACTU) is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug product, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy including several DNA Damage Response (DDR) pathways. Elraglusib is designed to act as a mediator of anti-tumor immunity through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and regulates multiple immune checkpoints and immune cell function. For additional information, please visit the Company’s website at http://www.actuatetherapeutics.com.

Headquarters

1751 River Run

Website

actuatetherapeutics.com

Industry

Pharmaceutical Manufacturing

Founded

2015

Stock Symbol

ACTU

NAICS

Pharmaceutical and Medicine Manufacturing, Medicinal and Botanical Manufacturing

Phone Number

Available in AeroLeads

Company Email

Available in AeroLeads

Actuate Therapeutics, Inc. Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

Actuate Therapeutics, Inc. People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

Compare Similar Companies to Actuate Therapeutics, Inc.

Explore companies in related markets and compare their industry and employee estimates.